Head and neck cancer trials in United Kingdom

In United Kingdom 39 Also abroad 942

39 trials · From ClinicalTrials.gov, checked 11 November 2026. Ask the study team whether a trial fits you.

Phase 1Taking people
A Study to Learn About the Study Medicine Called PF-08046876 in People With Advanced Solid Tumors
Where
London, Manchester
Age
18 years and over
People
540 worldwide
Run by
Pfizer
See details and how to joinNCT07090499 · EU 2025-521729-33-00
Phase 1Taking people
A Study of LY4052031 in Participants With Advanced or Metastatic Urothelial Cancer or Other Solid Tumors
Where
London, Manchester
Age
18 years and over
People
460 worldwide
Run by
Eli Lilly and Company
See details and how to joinNCT06465069 · EU 2024-512927-36-00
Phase 3Taking people
JNJ-90301900 (NBTXR3) Activated by Radiotherapy With or Without Cetuximab in LA-HNSCC
Where
Edinburgh, Glasgow, Guildford, London, Newcastle upon Tyne, Nottingham
Age
60 years and over
People
500 worldwide
Run by
Johnson & Johnson Enterprise Innovation Inc.
See details and how to joinNCT04892173 · EU 2024-520386-31-00
Phase 1/2Taking people
A Study of Amivantamab Alone or in Addition to Other Treatment Agents in Participants With Head and Neck Cancer
Where
Cambridge, Guildford, London, Manchester
Age
18 years and over
People
287 worldwide
Run by
Janssen Research & Development, LLC
See details and how to joinNCT06385080 · EU 2023-508418-40-00
Phase 3Taking people
A Study of Amivantamab in Addition to Standard of Care Agents (SOC) Compared With SOC Alone in Participants With Recurrent/Metastatic Head and Neck Cancer
Where
Cambridge, Cottingham, Edinburgh, Greater London, Guildford, London, Metropolitan Borough of Wirral, Northwood, Nottingham, Sutton
Age
18 years and over
People
600 worldwide
Run by
Janssen Research & Development, LLC
See details and how to joinNCT07276399 · EU 2025-521917-24-00
Phase 1/2Taking people
A Study of Bispecific Antibody MCLA-158 in Patients With Advanced Solid Tumors
Where
Cambridge, London
Age
18 years and over
People
560 worldwide
Run by
Genmab
See details and how to joinNCT03526835 · EU 2024-513627-16-01
Phase 2/3Taking people
FORTIFI-HN01: A Study of Ficerafusp Alfa (BCA101) or Placebo in Combination With Pembrolizumab in First-Line PD-L1-pos, R or M HNSCC
Where
Aberdeen, Birmingham, Cambridge, Glasgow, Leeds, Liverpool, London, Manchester, Middlesex, Newcastle upon Tyne, Nottingham, Oxford, Portsmouth, Sutton
Age
18 years and over
People
650 worldwide
Run by
Bicara Therapeutics
See details and how to joinNCT06788990 · EU 2024-519654-37-00
Phase 1Taking people
A Study of MGC026 in Participants With Advanced Solid Tumors
Where
Oxford, Sutton
Age
18 years and over
People
394 worldwide
Run by
MacroGenics
See details and how to joinNCT06242470
Phase 2/3Taking people
Ordastobart (INBRX-106) Add-on to Pembrolizumab in 1L HPV+ PD-L1+ R/M OPSCC (HexAgon-HN)
Where
Aberdeen, Cambridge, Chelsea, Manchester, Newcastle upon Tyne, Northwood, Norwich, Sutton
Age
18 years and over
People
450 worldwide
Run by
Inhibrx Biosciences, Inc
See details and how to joinNCT06295731
Phase 2Taking people
A Study of HER3-DXd in Subjects With Locally Advanced or Metastatic Solid Tumors
Where
Cambridge, Coventry, London, Nottingham
Age
18 years and over
People
740 worldwide
Run by
Daiichi Sankyo
See details and how to joinNCT06172478 · EU 2023-507641-29-00
Phase 3Taking people
A Study to Evaluate CRB-701 Compared to Investigator's Choice Therapy in Previously Treated Oropharyngeal Squamous Cell Carcinoma
Where
Birmingham, Cambridge, Glasgow, Liverpool, London, Manchester, Nottingham, Sutton
Age
18 years and over
People
260 worldwide
Run by
Corbus Pharmaceuticals Inc.
See details and how to joinNCT07768189 · EU 2026-527123-94-00
Phase 1/2Taking people
The Evaluation of PC14586 in Patients With Advanced Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE)
Where
London, Newcastle upon Tyne
Age
12 years and over
People
300 worldwide
Run by
PMV Pharmaceuticals, Inc
See details and how to joinNCT04585750
Phase 1Taking people
Study of Zanzalintinib in Combination With Immuno-Oncology or Other Agents in Participants With Solid Tumors
Where
Cambridge, London, Middlesex
Age
18 years and over
People
1,394 worldwide
Run by
Exelixis
See details and how to joinNCT05176483 · EU 2023-510061-10-00
Phase 3Taking people
A Global Study of Volrustomig (MEDI5752) for Participants With Unresected Locally Advanced Head and Neck Squamous Cell Carcinoma Following Definitive Concurrent Chemoradiotherapy
Where
Aberdeen, Cambridge, Hampshire, Leeds, London, Manchester, Metropolitan Borough of Wirral, Northwood, Sutton, Taunton
Age
18 years to 130 years
People
1,145 worldwide
Run by
AstraZeneca
See details and how to joinNCT06129864
No phaseTaking people
To Assess the Correlation of High-resolution Specimen PET-CT Imaging, Using the XEOS AURA 10 PET-CT, With the Histopathology Results and Long-term Outcome of Patients Undergoing Resective Cancer Surgery.
Where
Coventry
Age
18 years and over
People
850 worldwide
Run by
XEOS Medical
See details and how to joinNCT06970275
Phase 2Taking people
Study of Volrustomig as Monotherapy or in Combination With Anti- Cancer Agents in Participants With Advanced/Metastatic Solid Tumors
Where
Cambridge, Glasgow, Manchester
Age
18 years to 64 years
People
257 worldwide
Run by
AstraZeneca
See details and how to joinNCT06535607 · EU 2025-523947-36-00
Phase 1Taking people
A Study to Test the Safety, Tolerability and Effect of ZI-MA4-1 for Patients With Locally Advanced or Metastatic Solid Malignancies
Where
London, Manchester
Age
18 years to 75 years
People
9
Run by
Zelluna Immunotherapy AS
See details and how to joinNCT07613723
Phase 1/2Taking people
Safety and Efficacy of VB10.16 and Pembrolizumab in Patients With Head-Neck Squamous Cell Carcinoma
Where
London
Age
18 years and over
People
110 worldwide
Run by
Nykode Therapeutics ASA
See details and how to joinNCT06016920 · EU 2022-503055-26-00
Phase 1/2Taking people
Study to Assess GTAEXS617 in Participants With Advanced Solid Tumors
Where
Glasgow, London, Manchester, Newcastle upon Tyne, Oxford
Age
18 years and over
People
230 worldwide
Run by
Exscientia AI Ltd., a wholly owned subsidiary of Recursion Pharmaceuticals, Inc.
See details and how to joinNCT05985655
Phase 1Taking people
A Study of PF-08046054/SGN-PDL1V in Advanced Solid Tumors
Where
London, Sutton
Age
18 years and over
People
714 worldwide
Run by
Seagen, a wholly owned subsidiary of Pfizer
See details and how to joinNCT05208762 · EU 2023-506604-18-00
Phase 1Taking people
A Study of Sigvotatug Vedotin in Advanced Solid Tumors
Where
Birmingham, London, Sutton
Age
18 years and over
People
1,006 worldwide
Run by
Seagen, a wholly owned subsidiary of Pfizer
See details and how to joinNCT04389632 · EU 2023-508469-34-00
Phase 1Taking people
A Phase 1, First-in-human Study of OKN4395 and Pembrolizumab in Patients With Solid Tumors
Where
Glasgow, Leicester, London, Manchester, Oxford
Age
18 years and over
People
146 worldwide
Run by
Epkin
See details and how to joinNCT06789172
Phase 3Taking people
A Study of Dostarlimab vs Placebo After Chemoradiation in Adult Participants With Locally Advanced Unresected Head and Neck Squamous Cell Carcinoma
Where
Edinburgh, Gloucester, London, Nottingham, Sutton, Wolverhampton
Age
18 years and over
People
864 worldwide
Run by
GlaxoSmithKline
See details and how to joinNCT06256588 · EU 2023-508613-17-00
Phase 1/2Taking people
A Phase I/II Trial of UCB4594 in Participants With Advanced Cancer
Where
London, Manchester, Newcastle upon Tyne, Southampton
Age
18 years and over
People
167
Run by
Cancer Research UK
See details and how to joinNCT06380816
Phase 3Taking people
A Study of Ficlatuzumab in Combination With Cetuximab in Participants With Recurrent or Metastatic (R/M) HPV Negative Head and Neck Squamous Cell Carcinoma
Where
Aberdeen, London, Nottingham, Sutton, Torquay
Age
18 years and over
People
410 worldwide
Run by
AVEO Pharmaceuticals, Inc.
See details and how to joinNCT06064877 · EU 2023-505606-42-00